Diagnosis of iron deficiency in patients undergoing hemodialysis.

To diagnose iron deficiency in patients undergoing hemodialysis, the percentage of hypochromic RBCs (with cellular hemoglobin concentration <280 g/L [HYPO%]) and mean reticulocyte hemoglobin content (CHret) provided by the Siemens ADVIA 120 and 2120 analyzers (Siemens Diagnostic Solutions, Tarrytown, NY) were proposed as alternatives to biochemical tests. Sysmex, with its XE-5000 analyzer (Sysmex, Kobe, Japan), also proposed the percentage of erythrocytes with cellular hemoglobin content lower than 17 pg (%Hypo-He) and equivalent of the mean reticulocyte hemoglobin content (Ret-He) with similar clinical applications. Our aim was to verify the clinical usefulness of the biochemical and cellular parameters as predictors of iron deficiency in patients undergoing long-term hemodialysis. We studied 69 patients undergoing hemodialysis 3 times weekly. The baseline values of serum ferritin and percentage of transferrin saturation were poor predictors of iron responsiveness. Better ability was demonstrated by reticulocyte indices (area under the curve [AUC], 0.74 for CHret and 0.72 for Ret-He; best cutoff values, 31.2 and 30.6 pg, respectively) and erythrocyte parameters (AUC, 0.72 for HYPO% and 0.68 for %Hypo-He; best cutoff values, 5.8 and 2.7, respectively). The newly proposed Ret-He and %Hypo-He can provide clinicians with information equivalent to CHret and HYPO%.

[1]  C. Ihm,et al.  Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients , 2007, International journal of laboratory hematology.

[2]  Kdoqi.  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007 .

[3]  Ashutosh Kumar Singh,et al.  Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. , 2007, Kidney international.

[4]  P. Delanaye,et al.  Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  J. Berns,et al.  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  D. Coyne.  Challenging the boundaries of anemia management: a balanced approach to i.v. iron and EPO therapy. , 2006, Kidney international. Supplement.

[7]  Kdoqi.  III. Clinical practice recommendations for anemia in chronic kidney disease in children. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[8]  Kdoqi Disclaimer,et al.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  J. Linssen,et al.  Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis. , 2004, Clinical chemistry.

[10]  F. Locatelli,et al.  Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  M. Buttarello,et al.  The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia. , 2004, American journal of clinical pathology.

[12]  F. Gejyo,et al.  Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients. , 2003, Kidney international.

[13]  K. Mitsuiki,et al.  Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content , 2003, Clinical and Experimental Nephrology.

[14]  D. Tarng,et al.  Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  C. Chang,et al.  Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. , 2002, Clinical nephrology.

[16]  S. Fishbane,et al.  A randomized trial of iron deficiency testing strategies in hemodialysis patients. , 2001, Kidney international.

[17]  A. Lupo,et al.  The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  Ming-Yang Chang,et al.  Short-Term Small-Dose Intravenous Iron Trial to Detect Functional Iron Deficiency in Dialysis Patients , 2001, American Journal of Nephrology.

[19]  D. Marcelli,et al.  Nephrology Dialysis Transplantation the Impact of Haematocrit Levels and Erythropoietin Treatment on Overall and Cardiovascular Mortality and Morbidity—the Experience of the Lombardy Dialysis Registry Selected the Live Patients on Dialysis Treatment On , 2022 .

[20]  R. Mushnick,et al.  Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  S. Fishbane,et al.  Iron management in end-stage renal disease. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[22]  S. Fishbane,et al.  The evaluation of iron status in hemodialysis patients. , 1996, Journal of the American Society of Nephrology : JASN.

[23]  David C. Murray,et al.  The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  A. Morgan,et al.  Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  K. Braumann,et al.  Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. , 1991, Nephron.

[26]  J. Adamson,et al.  Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  D. Manninen,et al.  The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin , 1990 .

[28]  D. Manninen,et al.  The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. , 1990, JAMA.

[29]  J. T. Marsh,et al.  Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  B. Delano,et al.  Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  M. H. Metz,et al.  Flow-cytometric light scattering measurement of red blood cell volume and hemoglobin concentration. , 1985, Applied optics.